Linical Co., Ltd. has entered into a service contract with The Kitasato Institute regarding an investigator-initiated clinical trial for a new indication of ivermectin2 against the COVID-19 on September 9th, 2020. Linical will contribute to the health of patients, by applying Risk-Based Monitoring in this clinical trial, collecting highly reliable data contributing to the rapid and reliable development of this new indication.